Drug Trial Radar · NCT06106841
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
19
Actual
Start
Oct 5, 2023
Primary completion
Oct 16, 2024
Study completion Oct 16, 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.
Conditions
- Mantle Cell Lymphoma
Interventions
400mg of TQB3909 tabletsDrug
TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
600mg of TQB3909 tabletsDrug
TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (RP2D)Time frame: Baseline up to 48-weeks
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Chongqing University Hospital
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
The Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China
The Affiliated Hospital of Xuzhou Medical University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, China
Jinzhou Central Hospital
Wuxi, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Binzhou Medical University Hospital
Binzhou, Shandong, China
Linyi People's Hospital
Linyi, Shandong, China
Shanghai Huashan Hospital
Shanghai, Shanghai Municipality, China
Tongji hospital of Tongji University
Shanghai, Shanghai Municipality, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Institute of Dematology & Blood diseases Hospital
Tianjin, Tianjin Municipality, China
Xinjiang Uygur Autonomous Region People's Hospital
Ürümqi, Xinjiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.